GLP-1 Pipeline Trends: June 2026 Roundup (ADA Highlights, Survodutide Phase 3, Retatrutide Data, VK2735 Oral)

Helpful Products While Following GLP-1 Developments

If you are on a GLP-1 medication now or preparing to start, these help:

• Ginger chews — Proven nausea relief for the first weeks. Ginger chews are portable and fast-acting.
• Electrolyte packets — Dehydration makes side effects worse. LMNT packets are zero sugar and high sodium.
• Protein powder — Appetite drops fast on GLP-1s. A whey protein powder helps you hit daily protein goals.
• Smart scale — Track body composition, not just weight. A smart body scale syncs to your phone.

GLPSpot may earn from qualifying purchases.

Quick Summary: What Changed in June 2026

1. Survodutide: Phase 3 Results Published in Nature Medicine

On June 7, 2026, Boehringer Ingelheim reported results from two Phase 3 trials — SYNCHRONIZE-1 (obesity) and SYNCHRONIZE-MASLD (liver disease). The data was presented at ADA 2026 and published in Nature Medicine.

SYNCHRONIZE-1 (obesity): Met co-primary endpoints in adults with obesity or overweight without type 2 diabetes. Achieved sustained weight loss at the highest dose. Specific percentage data is pending full publication.

SYNCHRONIZE-MASLD (liver disease): This is the headline result:

• 34% visceral fat reduction — visceral fat is the metabolically harmful fat around internal organs
• 63% liver fat reduction — directly relevant for fatty liver disease (MASLD/MASH)
• Minimized lean mass loss — a differentiator vs other GLP-1s, which can cause significant muscle loss

This is the first GLP-1-class drug to show such strong MASH/MASLD data in Phase 3. The liver disease angle is significant because MASLD affects an estimated 30% of US adults and has very few effective treatments.

Survodutide works by targeting GLP-1 and glucagon receptors (a dual agonist). The glucagon part increases energy expenditure and appears to target liver fat directly — something GLP-1-only and GLP-1/GIP drugs do not do as effectively.

If the full Phase 3 program succeeds, FDA submission could come in 2027, with possible approval in 2027-2028.

For the full breakdown, see our Survodutide Guide.

2. Retatrutide: TRIUMPH-1 Full Data at ADA 2026

Eli Lilly presented detailed TRIUMPH-1 data at ADA 2026 in New Orleans. This is the Phase 3 trial for general obesity — the broadest patient population, and the one people have been waiting for.

Key numbers at the highest dose (12 mg) over 80 weeks:

• 28.3% average weight loss (70.3 lbs)
• 45.3% of participants reached ≥30% weight loss — a level previously associated with bariatric surgery
• 65.3% of participants dropped below BMI 30
• Waist circumference reduction of 9.5 inches

The extension data was even more striking: participants with BMI ≥35 who continued to 104 weeks reached 30.3% average weight loss (85 lbs) — the highest reported in any Phase 3 obesity trial to date.

Cardiometabolic improvements included reductions in non-HDL cholesterol, triglycerides, systolic blood pressure, and hsCRP (an inflammation marker).

Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) — targeting three pathways instead of one or two. The glucagon receptor increases energy expenditure, which is why the weight loss numbers exceed what dual-agonist or single-agonist drugs achieve.

Side effects: mostly gastrointestinal (nausea, diarrhea, constipation, vomiting). A notable finding: dysesthesia (tingling/burning sensation) affected 20.9% at 12 mg, mostly mild. About 11.3% discontinued due to side effects at the highest dose.

Retatrutide is not FDA-approved and is not available at any pharmacy. Several more Phase 3 trials are still running. The earliest likely FDA filing is late 2026 or 2027.

For the complete analysis, see our Retatrutide Guide.

3. VK2735: Oral Dual-Agonist Shows 12.2% Weight Loss in 13 Weeks

Viking Therapeutics presented Phase 2 data for oral VK2735 at ECO 2026 in May, and the data continues to generate discussion at ADA.

The VENTURE-Oral trial showed:

• 12.2% weight loss from baseline over 13 weeks at the highest oral dose
• All doses showed statistically significant weight loss vs placebo
• The weight loss trajectory had not plateaued at 13 weeks
• Side effects consistent with the GLP-1/GIP class (nausea, vomiting, diarrhea)

Why this matters: VK2735 is a dual GLP-1/GIP agonist being developed as both a pill and an injection. No other dual-agonist has an oral program this far along. If the oral form succeeds in Phase 3, it would be the first dual GLP-1/GIP agonist available as a pill — a significant advantage for people who cannot or will not do injections.

The tradeoff: VK2735 is still in Phase 2. Phase 3 has not started. Realistic timeline for approval is 2028-2029 at the earliest.

For more, see our VK2735 Guide.

4. CagriSema: Under FDA Review, Decision Expected Late 2026

CagriSema (semaglutide + cagrilintide) remains under FDA review. No new data this month, but the timeline is important:

• Novo Nordisk submitted its FDA application in late 2025
• FDA decision expected late 2026 or early 2027
• If approved, launch likely in 2027

Phase 3 REDEFINE 1 trial showed 20.4% average weight loss over 68 weeks — beating semaglutide alone (13.7%). The REIMAGINE-2 head-to-head trial showed CagriSema beat Ozempic directly: 14.2% vs 10.2% in people with type 2 diabetes.

CagriSema is the closest pipeline drug to approval. If it clears the FDA, it would be the first GLP-1 + amylin combination drug on the market.

For the full breakdown, see our CagriSema Guide.

5. Amycretin: Phase 2 Now Underway

Novo Nordisk's amycretin (GLP-1 + amylin pill) has moved into Phase 2 trials as of May 2026. Phase 1 data showed approximately 13% weight loss in 12 weeks — a promising early signal for a daily pill.

Amycretin is notable because it uses the same dual mechanism as CagriSema (GLP-1 + amylin) but in pill form instead of an injection. If it works, it could offer CagriSema-level weight loss without needles.

The timeline is long: earliest possible approval is 2029-2030.

For more, see our Amycretin vs Ozempic Guide.

6. The Oral GLP-1 Race: Who Is Winning?

The pill vs injection competition is the defining trend of 2026. Here is where the oral programs stand:

Foundayo is the only oral GLP-1 that is both approved and available without food restrictions. That makes it the current oral leader for convenience.

But the real competition is coming. If oral tirzepatide (Zepbound pill) maintains injection-level efficacy, it would be the strongest oral option. If VK2735 oral succeeds in Phase 3, it would be the first dual-agonist pill. If amycretin works, it would offer a new mechanism in pill form.

For now, Foundayo is the pill to beat.

7. Compounded Semaglutide: The Squeeze Continues

The compounding landscape shifted again in June 2026. Key developments:

• Semaglutide injection has been removed from the FDA Drug Shortage Database as of May 2026
• This means compounding pharmacies are supposed to stop making compounded semaglutide
• FDA enforcement actions (warning letters) have continued
• States including Texas, Florida, and California have added their own compounding regulations
• Some pharmacies still operate, but the legal risk is now higher

The practical impact: if you are using compounded semaglutide, verify your pharmacy carefully. Ask whether they use semaglutide base (not salt), request a certificate of analysis, and confirm they are a licensed 503A or 503B facility.

With Foundayo now available as a legitimate oral GLP-1 pill, patients who were using compounded semaglutide for cost or convenience reasons have a new FDA-approved alternative to consider.

For the full picture, see our Compounded Semaglutide 2026 Guide.

Pipeline Comparison: Where Every Drug Stands

These numbers come from different trials with different populations, durations, and designs. Cross-trial comparison is approximate — no drug can be definitively ranked against another without a head-to-head trial.

What to Watch for the Rest of 2026

1. CagriSema FDA decision — Expected late 2026 or early 2027. This is the next approval event on the calendar.
2. Retatrutide FDA filing — If Lilly announces a filing date, that locks in the timeline for the next blockbuster.
3. Remaining retatrutide Phase 3 trials — Sleep apnea, cardiovascular outcomes, and liver disease results are expected throughout 2026.
4. Survodutide full Phase 3 obesity data — SYNCHRONIZE-1 met endpoints, but the specific weight loss percentage is pending full publication. This matters for positioning against retatrutide.
5. Zepbound pill Phase 3 progress — Oral tirzepatide could be the strongest oral option if it maintains injection-level efficacy.
6. Medicare GLP-1 coverage expansion — The Medicare bridge program for GLP-1 weight loss medications continues to roll out. More on this in our Medicare GLP-1 Guide.
7. Supply improvements — Most Wegovy and Ozempic doses are now more available. Watch for continued stabilization through late 2026.

The Bottom Line

June 2026 is a high-water mark for GLP-1 pipeline activity. Three drugs reported major new data in the same month. CagriSema sits at the FDA's doorstep. Retatrutide's numbers continue to set records. Survodutide carved out a niche in liver disease. VK2735 proved the oral dual-agonist concept.

But none of these pipeline drugs are available today. If you need treatment now, five FDA-approved GLP-1 medications are already on the market. Start with what works today. You can always switch to a newer drug if one gets approved and turns out to be better for you.

The GLP-1 space is moving fast. The best strategy: stay informed, work with your doctor, and make decisions based on what is available — not what might be.

This article is for informational purposes only and does not constitute medical advice. Drugs mentioned as "in trials" or "under review" are not FDA-approved unless explicitly stated. Always talk to your healthcare provider before starting, stopping, or changing any medication.

Related Reading

• Survodutide: The Next GLP-1 Weight Loss Drug
• Retatrutide Guide: TRIUMPH-1 Phase 3 Results
• VK2735 Guide: Viking Therapeutics' Dual GLP-1/GIP Drug
• CagriSema: What It Is and When It's Coming
• Amycretin vs Ozempic: What We Know
• Semaglutide News: May 2026 Updates
• Foundayo (Orforglipron): GLP-1 Pill With No Food Rules
• Best GLP-1 for Weight Loss in 2026